Nanjing IASO Biotechnology Co., Ltd. (IASO
Bio) made its debut at the 6 th  China International Import Expo (CIIE) with FUCASO, the
worlds first fully-human CAR-T, and entered into a strategic partnership with several
international medical institutions, bringing hope for cure to multiple myeloma (MM)
patients worldwide. On June 30, 2023, the China National Medical Products Administration (NMPA) approved the marketing of Equecabtagene Autoleucel Injection (brand name: FUCASO)
for the treatment of adult patients with relapsed or refractory multiple myeloma (r/rMM).
Meanwhile, the Equecabtagene Autoleucel Injection has received the Orphan Drug
Designation, as well as the Regenerative Medicine Advanced Therapy and Fast Track
Designations from the U.S. Food and Drug Administration, and has been approved for
clinical trials in the U.S. A single infusion of FUCASO can lead to lasting and deep remission with a favorable safety profile in patients with r/rMM who have failed multiple lines of therapy. Due to its
unique design, FUCASO, as a fully-human CAR-T therapy, is able to persist in patients
for a longer period of time, offering hope for overcoming the challenging problem of
relapsed MM. FUCASO has attracted patients from numerous countries around the world to seek
treatment in Chinese hospitals in just 4 months since its approval for marketing in
China. These hospitals have a world-leading level of full-process management in CAR-
T therapy. In addition, the cost of treatment with FUCASO in China is significantly lower
than that of